Study Of Combination Therapy With Ipratropium Bromide And Levosalbutamol In Stable Chronic Obstructive Pulmonary Disease Patients.
Ipratropium Bromide And Levosalbutamol In Stable Chronic Obstructive Pulmonary Disease Patients
DOI:
https://doi.org/10.70284/njirm.v6i3.914Keywords:
COPD, Ipratropium Bromide, LevosalbutamolAbstract
Background: This study compared the efficacy of levosalbutamol alone and ipratropium bromide alone with levosalbutamol and ipratropium bromide combined, through inhalational route in stable patients of chronic obstructive pulmonary disease (COPD). The study was carried out in 102 patients of COPD. Levosalbutamol inhalation was administered to 33 patients and ipratropium bromide inhalation was given to 31 patients.38 patients were treated with combination of levosalbutamol and ipratropium bromide inhalation. Pulmonary functions were noted before and after 15, 30, 60,120,180 and 240 minutes of inhalation of these drugs. Bronchodilation was significantly more in patients treated with combination therapy as compared to patients treated with single drug separately. The effect was more sustained in combination therapy as it started declining after 120 minutes with levosalbutamol, after 180 minutes in ipratropium bromide and after 240 minutes with combination therapy. So it was concluded that combination therapy with levosalbutamol and ipratropium bromide is better in management of COPD patients than using either of agents alone. [Kamshette Y NJIRM 2015; 6(3):60-63]
References
2. Bhargava R,Sharma DK et al,combination therapy with salbutamol and ipratropium bromide in stable patients with COPD,Lung India (1999),XVII,NO.1(P15-18)
3. Grassi V, Bruni B,Peccini F et al . Acute and chronic comparative effects of combination of fenoterol,ipratropium bromide and terbutaline in patients with chronic obstructive lung disease, respiration 1986;50:pages226-31
4. BR O’Driscol, MG Horsley et al ,Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. The Lancet, Vol 333:pages1418-1420
5. Comparison of nebulised ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation. ,Annals of Allergy, Asthma and Immunology, Volume 96,issue 5:pages701-706
6. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate to severe persistent asthma ,Pulmonary pharmacology and therapeutics, Vol 21,Issue4:pages630-636
7. David C Levin, Katherine s little et al, Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with COPD,The American journal of Medicine,Vol 100,supplement1,pages s40-s48.
8. Patel M, Thomson NC, levosalbutamol for COPD :treatment evaluation, expert opinion on pharmacotherapy,2012.
9. James F, Nicola A, comparison of lev-albuterol and racemic albuterol in hospitalized patients of acute asthma , COPD. Clinical Therapeutics 2008.
10. Maiti R, Prasad CM, racemic salbutamol and levosalbutamolin mild persistent asthma: comparative study of efficacy and safety, Indian journal of pharmacology,2011
11. Peter J. Barnes. Emerging Pharmacotherapies for COPD. Chest 2008;134;1278-1286
12. Peter J. Barnes. Future Treatments for Chronic Obstructive Pulmonary Disease and Its Co morbidities. The Proceedings of the American Thoracic Society 2008;5:857-864
13. Satomi Onoue, Shinger Misaka, Yohei Kawabata and Shizuo Yamada. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin. Drug Deliv 2009;6:793-811.
14. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends in Pharmacological Sciences 2011;1-12. Article in Press.
15. M. Cazzola and M.G. Matera. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757–769.
16. M Cazzola and MG Matera. Novel long-acting bronchodilators for COPD and Asthma. British Journal of Pharmacology 2008;155:291–299
17. Gross NJ, Petty TL et al, dose response to ipratropium bromide as nebulised solution in patients with COPD, American Rev respiratory Disease, 1989, vol 139:1188-1191.
18. Van Schayk, Folgering H et al ,Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991,vol 46:355-359
19. Combivent Inhalational aerosol study group. CHEST 1994,vol 105:1411-1419.
20. The Combivent inhalational aerosol study group, Routine nebulized ipratropium and albuterol together inCOPD. Chest 1997,vol 112,1514-1521.
